Integra LifeSciences Holdings Corporation

NasdaqGS:IART Lagerbericht

Marktkapitalisierung: US$2.5b

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Integra LifeSciences Holdings Management

Management Kriterienprüfungen 4/4

Integra LifeSciences Holdings' CEO ist Jan De Witte, ernannt in Dec 2021, hat eine Amtszeit von 2.42 Jahren. Die jährliche Gesamtvergütung beträgt $6.39M, bestehend aus 13.7% Gehalt und 86.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.023% der Aktien des Unternehmens, im Wert von $519.56K. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.9 Jahre bzw. 11 Jahre.

Wichtige Informationen

Jan De Witte

Geschäftsführender

US$6.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts13.7%
Amtszeit als Geschäftsführer2.5yrs
Eigentum des Geschäftsführers0.02%
Durchschnittliche Amtszeit des Managements4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder11.1yrs

Jüngste Management Updates

Recent updates

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

May 28
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

Feb 27
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Feb 11
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jan 14
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Dec 31
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Dec 03
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Nov 06
Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Oct 24
Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Sep 22
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Aug 15
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Jul 03
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jun 19
Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

May 05
Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Apr 07
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

Mar 26
Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Mar 14
At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Feb 27
Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Feb 02
Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Jan 05
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

Dec 21
Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Dec 08
When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?

Oct 19
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Oct 05
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Integra LifeSciences: Wide Dislocation In Fundamentals Vs. Market Value

Sep 13

Is It Time To Consider Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Sep 06
Is It Time To Consider Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

FDA labels recall of intracranial pressure monitors by Integra as most serious

Aug 31

Integra Lifesciences voluntarily recalls pressure monitors, lowers revenue, profit guidance

Aug 24

Returns At Integra LifeSciences Holdings (NASDAQ:IART) Appear To Be Weighed Down

Aug 23
Returns At Integra LifeSciences Holdings (NASDAQ:IART) Appear To Be Weighed Down

Integra LifeSciences founder/former CEO dies

Aug 16

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Jan De Witte im Vergleich zu den Einnahmen von Integra LifeSciences Holdings verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2024n/an/a

US$40m

Dec 31 2023US$6mUS$875k

US$68m

Sep 30 2023n/an/a

US$101m

Jun 30 2023n/an/a

US$131m

Mar 31 2023n/an/a

US$172m

Dec 31 2022US$9mUS$850k

US$181m

Sep 30 2022n/an/a

US$173m

Jun 30 2022n/an/a

US$166m

Mar 31 2022n/an/a

US$157m

Dec 31 2021US$899kUS$59k

US$169m

Vergütung im Vergleich zum Markt: JanDie Gesamtvergütung ($USD6.39M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD5.67M).

Entschädigung vs. Einkommen: JanDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.


Geschäftsführer

Jan De Witte (60 yo)

2.5yrs

Amtszeit

US$6,388,756

Vergütung

Mr. Jan De Witte has been President, Chief Executive Officer & Director of Integra LifeSciences Holdings Corporation since December 1, 2021. He had been the Chief Executive Officer at Barco NV since Septem...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Stuart Essig
Executive Chairman26.5yrsUS$422.52k2.23%
$ 55.9m
Jan De Witte
President2.5yrsUS$6.39m0.023%
$ 584.7k
Lea Knight
Executive VP & CFOless than a yearUS$1.67m0.056%
$ 1.4m
Jeffrey Mosebrook
Senior VP of Finance & Principal Accounting Officer6.7yrsUS$1.25m0.034%
$ 857.9k
Eric Schwartz
Executive VP5.6yrsUS$1.62m0.081%
$ 2.0m
Robert Davis
Executive VP & President of Tissue Technologies11.5yrsUS$1.42m0.083%
$ 2.1m
Michael McBreen
Executive VP & President of Codman Specialty Surgical4.1yrsUS$2.83m0.073%
$ 1.8m
Stephen Leonard
Corporate VP of Global Operations & Supply Chain3.8yrskeine Datenkeine Daten
Mathieu Aussermeier
Vice President of Corporate Financeno datakeine Datenkeine Daten
William Compton
Chief Information Officer & Corporate VPno datakeine Datenkeine Daten
Laurene Isip
Vice President of Global Corporate Communications & Public Relationsno datakeine Datenkeine Daten
Ruth Fleming
Vice President of Global Marketingno datakeine Datenkeine Daten

4.0yrs

Durchschnittliche Betriebszugehörigkeit

58.5yo

Durchschnittliches Alter

Erfahrenes Management: IARTDas Führungsteam des Unternehmens gilt als erfahren (3.9 Jahre durchschnittliche Betriebszugehörigkeit).


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Stuart Essig
Executive Chairman26.5yrsUS$422.52k2.23%
$ 55.9m
Jan De Witte
President2.5yrsUS$6.39m0.023%
$ 584.7k
Raymond Murphy
Independent Director15.2yrsUS$297.54k0.11%
$ 2.6m
Christian Schade
Independent Director18.4yrsUS$293.28k0.081%
$ 2.0m
Barbara Hill
Independent Presiding Director11.1yrsUS$342.54k0.17%
$ 4.4m
Keith N. Bradley
Independent Director32.4yrsUS$306.31k0.089%
$ 2.2m
Jeffrey Graves
Independent Directorless than a yearUS$90.68k0.016%
$ 398.2k
Shaundra Clay
Independent Director3.2yrsUS$260.04k0.028%
$ 698.4k
Renee Lo
Independent Director1.9yrsUS$297.54k0.021%
$ 514.7k

11.1yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: IARTDie Vorstandsmitglieder sind sehr erfahren ( 11 ).